Edition:
India

Jounce Therapeutics Inc (JNCE.OQ)

JNCE.OQ on NASDAQ Stock Exchange Global Select Market

6.63USD
25 Sep 2018
Change (% chg)

$-0.03 (-0.45%)
Prev Close
$6.66
Open
$6.69
Day's High
$6.84
Day's Low
$6.60
Volume
22,744
Avg. Vol
159,288
52-wk High
$29.02
52-wk Low
$6.30

Summary

Name Age Since Current Position

Richard Murray

59 2014 President, Chief Executive Officer, Director

Kimberlee Drapkin

50 2015 Chief Financial Officer, Treasurer

Hugh Cole

53 2017 Chief Business Officer and Head of Corporate Development

Elizabeth Trehu

58 2015 Chief Medical Officer

J. Duncan Higgons

63 2015 Independent Director

Robert Tepper

62 2013 Independent Director

Biographies

Name Description

Richard Murray

Dr. Richard Murray, Ph.D. is the President, Chief Executive Officer and Director of Jounce Therapeutics, Inc. Prior to joining Jounce, Dr. Murray served as senior vice president of biologics and vaccines research and development at Merck & Co., a global healthcare company, from 2009 to June 2014, where he was responsible for the advancement of biologics and vaccines, including Merck's cancer immunotherapy pipeline. From 2008 to 2009, Dr. Murray served as an advisor to venture capital and life science investors. From 2003 to 2008, he served in a variety of roles at PDL Biopharma Inc., or PDL, initially as vice president of research to executive vice president and chief scientific officer. He also served as a director of PDL from 2007 to 2008. Earlier in his career, Dr. Murray was a co-founder and served as vice president of research at Eos Biotechnology, Inc. Dr. Murray holds a Ph.D. in microbiology and immunology from the University of North Carolina at Chapel Hill and a B.S. in microbiology from the University of Massachusetts, Amherst. We believe that Dr. Murray is qualified to serve on our board of directors due to his operating and historical experience gained from serving as our president, chief executive officer and as a board member, combined with his experience in drug research and development.

Kimberlee Drapkin

Ms. Kimberlee Cobleigh Drapkin, CPA is the Chief Financial Officer and Treasurer of Jounce Therapeutics, Inc. Ms. Drapkin was the owner of KCD Financial LLC, through which she served as our interim chief financial officer from 2012 to August 2015, and consulted for numerous biotechnology companies. Previously, Ms. Drapkin served as the chief financial officer of Predix Pharmaceuticals Holdings, Inc. from 2005 to 2006, and, after Predix was acquired by EPIX Pharmaceuticals, Inc., as chief financial officer of EPIX from 2006 to 2009. From 1995 to 2005, Ms. Drapkin served in a variety of roles at Millennium Pharmaceuticals, Inc., including director of finance. Ms. Drapkin began her career at PricewaterhouseCoopers LLP, is a certified public accountant and holds a B.S. in accounting from Babson College.

Hugh Cole

Mr. Hugh M. Cole is Chief Business Officer and Head of Corporate Development of the company. Prior to joining Jounce in August 2017, Mr. Cole served as chief business officer for ARIAD Pharmaceuticals, Inc., an oncology company, from March 2014 to June 2017, where he led numerous business development transactions. Previously, Mr. Cole served as senior vice president, strategic planning and program management at Shire plc, a global biopharmaceutical company, from 2007 to March 2014. At Shire, Mr. Cole's responsibilities included the global development strategy and commercialization of the rare disease drug Firazyr. Earlier in his career, Mr. Cole was vice president, corporate development for Oscient Pharmaceuticals, Inc. and served as senior director, business development and strategy at Millennium Pharmaceuticals, Inc. Mr. Cole earned his M.B.A. in health care management and finance at the Wharton School of Business and his A.B. in chemistry from Harvard University.

Elizabeth Trehu

Dr. Elizabeth G. Trehu, M.D. is the Chief Medical Officer of the Company. Prior to joining Jounce, Dr. Trehu served as the chief medical officer of Promedior, Inc., a biotechnology company, from 2012 to November 2015. Previously, Dr. Trehu served as vice president, product development and medical affairs for Infinity Pharmaceuticals, Inc. from 2010 to 2012. Earlier in her career, Dr. Trehu served in a variety of roles for Genzyme Corporation, including as the vice president and general manager, hematology from 2009 to 2010, vice president and general manager of Clolar from 2008 to 2009 and vice president, global medical affairs of Genzyme Oncology from 2006 to 2008. Earlier in her career, Dr. Trehu served from 2002 to 2006 in a variety of positions at Millennium Pharmaceuticals, Inc., including as vice president of oncology global medical affairs in 2006. Dr. Trehu holds an M.D. from the New York University School of Medicine and an A.B. in English from Princeton University.

J. Duncan Higgons

Mr. J. Duncan Higgons is an Independent Director of the Company. Mr. Higgons served as chief operating officer of Agios Therapeutics, Inc., or Agios, a public biopharmaceutical company, from 2009 to January 2016. Prior to joining Agios, Mr. Higgons served as executive vice-president, and interim president and chief executive officer at Archemix Corporation, or Archemix, from 2006 to 2009. Prior to Archemix, Mr. Higgons served as the chief commercial officer at TransForm Pharmaceuticals, Inc., which was acquired by Johnson & Johnson Company. Mr. Higgons serves on the board of PsiOxus Therapeutics Ltd., a private cancer therapeutics company. He holds a B.Sc. in Mathematics from King's College University of London and a M.Sc. in Economics from London Business School. We believe that Mr. Higgons is qualified to serve on our board of directors due to his leadership and management experience.

Robert Tepper

Dr. Robert I. Tepper M.D. is an Independent Director of the Company. Since 2007, Dr. Tepper has served as a partner at Third Rock Ventures, LLC, a venture capital fund, which he co-founded in 2007. From February 2013 to January 2015, Dr. Tepper served as our interim chief scientific officer and, from October 2015 to November 2016, he served as the interim chief scientific officer of Neon Therapeutics, Inc., an immuno-oncology company. Prior to joining Third Rock Ventures, LLC, Dr. Tepper held multiple positions at Millennium Pharmaceuticals, Inc., including as president of research and development from 2002 to 2007, executive vice president of discovery from 2001 to 2002 and chief scientific officer from 1999 to 2002. Dr. Tepper serves on the boards of directors for numerous companies, including publicly-traded companies Allena Pharmaceuticals, Inc. and Kala Pharmaceuticals, Inc., and private companies Constellation Pharmaceuticals, Inc. and Neon Therapeutics, Inc. Previously, Dr. Tepper served on the board of directors of Bluebird Bio, Inc. from September 2010 through March 2015 and various other private life science companies. Dr. Tepper received an M.D. from Harvard Medical School and an A.B. in biochemistry from Princeton University. We believe that Dr. Tepper is qualified to serve on our board of directors due to his experience in the venture capital industry, particularly with biotech and pharmaceutical companies, combined with his experience building and leading research and development operations, serving on the boards of public and private life sciences companies and as faculty and advisory board members of several healthcare institutions.

Basic Compensation

Name Fiscal Year Total

Richard Murray

750,258

Kimberlee Drapkin

875,245

Hugh Cole

2,174,690

Elizabeth Trehu

513,558

J. Duncan Higgons

--

Robert Tepper

--
As Of  31 Dec 2017

Options Compensation